Citation 88005

TRAN,QL: TEZUKA,Y: BANSKOTA,AH: TRAN,QK: SAIKI,I: KADOTA,S:. (2001). NEW SPIROSTANOL STEROIDS AND STEROIDAL SAPONINS FROM ROOTS AND RHIZOMES OF DRACAENA ANGUSTIFOLIA AND THEIR ANTIPROLIFERATIVE ACTIVITY.. 64(9)

Citation Details

Title	NEW SPIROSTANOL STEROIDS AND STEROIDAL SAPONINS FROM ROOTS AND RHIZOMES OF DRACAENA ANGUSTIFOLIA AND THEIR ANTIPROLIFERATIVE ACTIVITY.
Authors	TRAN,QL: TEZUKA,Y: BANSKOTA,AH: TRAN,QK: SAIKI,I: KADOTA,S:
Year	2001
Volume	64
Issue	9

Summary

Year: 2001

Journal: Unknown

Organisms and Their Experiments (1)

Dracaena angustifolia (AGAVACEAE)

Experiment #	Pharmacology Type	Worktypes	Compound	Results
1	Not specified	VOUCHER SPECIMEN REPORTED FOR	None	None
2	ANTIPROLIFERATION ACTIVITY	PHARMACOLOGY OF EXTRACT - IN VITRO	None	ACTIVE
3	ANTIPROLIFERATION ACTIVITY	PHARMACOLOGY OF EXTRACT - IN VITRO	None	INACTIVE
4	Not specified	MASS-SPECTRAL FRAGMENTATION REPORTEDPMR SPECTRUM REPORTEDCMR SPECTRUM REPORTEDQUANTITATIVE DATAISOLATION OF A COMPOUND WITH NOVEL STRUCTURE	NAMOGENIN A,25(R):	None
5	ANTIPROLIFERATION ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VITRO	NAMOGENIN A,25(R):NAMOGENIN A,25(S):	INACTIVE
6	ANTIPROLIFERATION ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VITRO	NAMOGENIN A,25(R):NAMOGENIN A,25(S):	INACTIVE
7	ANTIPROLIFERATION ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VITRO	NAMOGENIN A,25(R):NAMOGENIN A,25(S):	INACTIVE
8	Not specified	MASS-SPECTRAL FRAGMENTATION REPORTEDPMR SPECTRUM REPORTEDCMR SPECTRUM REPORTEDQUANTITATIVE DATAISOLATION OF A COMPOUND WITH NOVEL STRUCTURE	NAMOGENIN A,25(S):	None
9	Not specified	MASS-SPECTRAL FRAGMENTATION REPORTEDPMR SPECTRUM REPORTEDCMR SPECTRUM REPORTEDQUANTITATIVE DATAISOLATION OF A COMPOUND WITH NOVEL STRUCTURE	NAMOGENIN B	None
10	ANTIPROLIFERATION ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VITRO	NAMOGENIN BNAMOGENIN C	INACTIVE
11	ANTIPROLIFERATION ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VITRO	NAMOGENIN BNAMOGENIN C	INACTIVE
12	ANTIPROLIFERATION ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VITRO	NAMOGENIN BNAMOGENIN C	INACTIVE
13	Not specified	MASS-SPECTRAL FRAGMENTATION REPORTEDPMR SPECTRUM REPORTEDCMR SPECTRUM REPORTEDQUANTITATIVE DATAISOLATION OF A COMPOUND WITH NOVEL STRUCTURE	NAMOGENIN C	None
14	Not specified	MASS-SPECTRAL FRAGMENTATION REPORTEDPMR SPECTRUM REPORTEDCMR SPECTRUM REPORTEDQUANTITATIVE DATAISOLATION OF A COMPOUND WITH NOVEL STRUCTURE	NAMONIN A	None
15	ANTIPROLIFERATION ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VITRO	NAMONIN A	ACTIVE
16	ANTIPROLIFERATION ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VITRO	NAMONIN A	ACTIVE
17	ANTIPROLIFERATION ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VITRO	NAMONIN A	ACTIVE
18	Not specified	MASS-SPECTRAL FRAGMENTATION REPORTEDPMR SPECTRUM REPORTEDCMR SPECTRUM REPORTEDQUANTITATIVE DATAISOLATION OF A COMPOUND WITH NOVEL STRUCTURE	NAMONIN B	None
19	ANTIPROLIFERATION ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VITRO	NAMONIN B	ACTIVE
20	ANTIPROLIFERATION ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VITRO	NAMONIN B	ACTIVE
21	ANTIPROLIFERATION ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VITRO	NAMONIN B	ACTIVE
22	Not specified	MASS-SPECTRAL FRAGMENTATION REPORTEDPMR SPECTRUM REPORTEDCMR SPECTRUM REPORTEDQUANTITATIVE DATAISOLATION OF A COMPOUND WITH NOVEL STRUCTURE	NAMONIN C	None
23	ANTIPROLIFERATION ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VITRO	NAMONIN C	INACTIVE
24	ANTIPROLIFERATION ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VITRO	NAMONIN C	ACTIVE
25	ANTIPROLIFERATION ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VITRO	NAMONIN C	INACTIVE
26	Not specified	MASS-SPECTRAL FRAGMENTATION REPORTEDPMR SPECTRUM REPORTEDCMR SPECTRUM REPORTEDQUANTITATIVE DATAISOLATION OF A COMPOUND WITH NOVEL STRUCTURE	NAMONIN D	None
27	ANTIPROLIFERATION ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VITRO	NAMONIN D	ACTIVE
28	ANTIPROLIFERATION ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VITRO	NAMONIN D	ACTIVE
29	ANTIPROLIFERATION ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VITRO	NAMONIN D	ACTIVE
30	Not specified	MASS-SPECTRAL FRAGMENTATION REPORTEDPMR SPECTRUM REPORTEDCMR SPECTRUM REPORTEDQUANTITATIVE DATAISOLATION OF A COMPOUND WITH NOVEL STRUCTURE	NAMONIN E	None
31	ANTIPROLIFERATION ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VITRO	NAMONIN E	INACTIVE
32	ANTIPROLIFERATION ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VITRO	NAMONIN E	ACTIVE
33	ANTIPROLIFERATION ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VITRO	NAMONIN E	INACTIVE
34	Not specified	MASS-SPECTRAL FRAGMENTATION REPORTEDPMR SPECTRUM REPORTEDCMR SPECTRUM REPORTEDQUANTITATIVE DATAISOLATION OF A COMPOUND WITH NOVEL STRUCTURE	NAMONIN F	None
35	ANTIPROLIFERATION ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VITRO	NAMONIN F	INACTIVE
36	ANTIPROLIFERATION ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VITRO	NAMONIN F	INACTIVE
37	ANTIPROLIFERATION ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VITRO	NAMONIN F	INACTIVE
38	Not specified	ISOLATION AND IDENTIFICATION OFQUANTITATIVE DATA	SPIROSTA-5-25(27)-DIEN-1-BETA-3-BETA-23(S)-24(S)-TETROL-1-O{[2-3-4-TRI-O-ACETYL-ALPHA-L-RHAMNOPYRANOSYL(1-2)]-[BETA-D-XYLOPYRANOSYL(1-3)]-ALPHA-L-ARABINOPYRANOSIDE}-24-O-BETA-D-FUCOPYRANOSIDE	None
39	ANTIPROLIFERATION ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VITRO	SPIROSTA-5-25(27)-DIEN-1-BETA-3-BETA-23(S)-24(S)-TETROL-1-O{[2-3-4-TRI-O-ACETYL-ALPHA-L-RHAMNOPYRANOSYL(1-2)]-[BETA-D-XYLOPYRANOSYL(1-3)]-ALPHA-L-ARABINOPYRANOSIDE}-24-O-BETA-D-FUCOPYRANOSIDE	ACTIVE
40	ANTIPROLIFERATION ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VITRO	SPIROSTA-5-25(27)-DIEN-1-BETA-3-BETA-23(S)-24(S)-TETROL-1-O{[2-3-4-TRI-O-ACETYL-ALPHA-L-RHAMNOPYRANOSYL(1-2)]-[BETA-D-XYLOPYRANOSYL(1-3)]-ALPHA-L-ARABINOPYRANOSIDE}-24-O-BETA-D-FUCOPYRANOSIDE	ACTIVE
41	ANTIPROLIFERATION ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VITRO	SPIROSTA-5-25(27)-DIEN-1-BETA-3-BETA-23(S)-24(S)-TETROL-1-O{[2-3-4-TRI-O-ACETYL-ALPHA-L-RHAMNOPYRANOSYL(1-2)]-[BETA-D-XYLOPYRANOSYL(1-3)]-ALPHA-L-ARABINOPYRANOSIDE}-24-O-BETA-D-FUCOPYRANOSIDE	ACTIVE
42	Not specified	ISOLATION AND IDENTIFICATION OFQUANTITATIVE DATA	SPIROSTA-5-25(27)-DIEN-1-BETA-3-BETA-23(S)-24(S)-TETROL-1-O-[2-3-4-TRI-O-ACETYL-ALPHA-L-RHAMNOPYRANOSYL(1-2)-ALPHA-L-ARABINOPYRANOSIDE]-24-O-BETA-D-FUCOPYRANOSIDE	None
43	ANTIPROLIFERATION ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VITRO	SPIROSTA-5-25(27)-DIEN-1-BETA-3-BETA-23(S)-24(S)-TETROL-1-O-[2-3-4-TRI-O-ACETYL-ALPHA-L-RHAMNOPYRANOSYL(1-2)-ALPHA-L-ARABINOPYRANOSIDE]-24-O-BETA-D-FUCOPYRANOSIDE	ACTIVE
44	ANTIPROLIFERATION ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VITRO	SPIROSTA-5-25(27)-DIEN-1-BETA-3-BETA-23(S)-24(S)-TETROL-1-O-[2-3-4-TRI-O-ACETYL-ALPHA-L-RHAMNOPYRANOSYL(1-2)-ALPHA-L-ARABINOPYRANOSIDE]-24-O-BETA-D-FUCOPYRANOSIDE	ACTIVE
45	ANTIPROLIFERATION ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VITRO	SPIROSTA-5-25(27)-DIEN-1-BETA-3-BETA-23(S)-24(S)-TETROL-1-O-[2-3-4-TRI-O-ACETYL-ALPHA-L-RHAMNOPYRANOSYL(1-2)-ALPHA-L-ARABINOPYRANOSIDE]-24-O-BETA-D-FUCOPYRANOSIDE	ACTIVE
46	Not specified	ISOLATION AND IDENTIFICATION OFQUANTITATIVE DATA	SPIROSTA-5-25(27)-DIEN-1-BETA-3-BETA-23(S)-24(S)-TETROL-1-O-{[2-3-4-TRI-O-ACETYL-ALPHA-L-RHAMNOPYRANOSYL(1-2)]-[BETA-D-XYLOPYRANOSYL(1-3)]}-ALPHA-L-ARABINOPYRANOSIDE	None
47	ANTIPROLIFERATION ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VITRO	SPIROSTA-5-25(27)-DIEN-1-BETA-3-BETA-23(S)-24(S)-TETROL-1-O-{[2-3-4-TRI-O-ACETYL-ALPHA-L-RHAMNOPYRANOSYL(1-2)]-[BETA-D-XYLOPYRANOSYL(1-3)]}-ALPHA-L-ARABINOPYRANOSIDE	ACTIVE
48	ANTIPROLIFERATION ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VITRO	SPIROSTA-5-25(27)-DIEN-1-BETA-3-BETA-23(S)-24(S)-TETROL-1-O-{[2-3-4-TRI-O-ACETYL-ALPHA-L-RHAMNOPYRANOSYL(1-2)]-[BETA-D-XYLOPYRANOSYL(1-3)]}-ALPHA-L-ARABINOPYRANOSIDE	ACTIVE
49	ANTIPROLIFERATION ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VITRO	SPIROSTA-5-25(27)-DIEN-1-BETA-3-BETA-23(S)-24(S)-TETROL-1-O-{[2-3-4-TRI-O-ACETYL-ALPHA-L-RHAMNOPYRANOSYL(1-2)]-[BETA-D-XYLOPYRANOSYL(1-3)]}-ALPHA-L-ARABINOPYRANOSIDE	ACTIVE
50	Not specified	ISOLATION AND IDENTIFICATION OFQUANTITATIVE DATA	SPIROSTA-5-25(27)-DIEN-1-BETA-3-BETA-23(S)-24(S)-TETROL-1-O-[ALPHA-L-RHAMNOPYRANOSYL(1-2)}-ALPHA-L-ARABINOPYRANOSIDE	None
51	ANTIPROLIFERATION ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VITRO	SPIROSTA-5-25(27)-DIEN-1-BETA-3-BETA-23(S)-24(S)-TETROL-1-O-[ALPHA-L-RHAMNOPYRANOSYL(1-2)}-ALPHA-L-ARABINOPYRANOSIDE	ACTIVE
52	ANTIPROLIFERATION ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VITRO	SPIROSTA-5-25(27)-DIEN-1-BETA-3-BETA-23(S)-24(S)-TETROL-1-O-[ALPHA-L-RHAMNOPYRANOSYL(1-2)}-ALPHA-L-ARABINOPYRANOSIDE	ACTIVE
53	ANTIPROLIFERATION ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VITRO	SPIROSTA-5-25(27)-DIEN-1-BETA-3-BETA-23(S)-24(S)-TETROL-1-O-[ALPHA-L-RHAMNOPYRANOSYL(1-2)}-ALPHA-L-ARABINOPYRANOSIDE	ACTIVE
54	Not specified	ISOLATION AND IDENTIFICATION OFQUANTITATIVE DATA	FUROSTA-5-20(22)-25(27)-TRIEN-1-BETA-3-BETA-26-TRIOL-1-O-[ALPHA-L-RHAMNOPYRANOSYL(1-2)-ALPHA-L-ARABINOPYRANOSIDE]-26-O-BETA-D-GLUCOPYRANOSIDE	None
55	ANTIPROLIFERATION ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VITRO	FUROSTA-5-20(22)-25(27)-TRIEN-1-BETA-3-BETA-26-TRIOL-1-O-[ALPHA-L-RHAMNOPYRANOSYL(1-2)-ALPHA-L-ARABINOPYRANOSIDE]-26-O-BETA-D-GLUCOPYRANOSIDE	INACTIVE
56	ANTIPROLIFERATION ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VITRO	FUROSTA-5-20(22)-25(27)-TRIEN-1-BETA-3-BETA-26-TRIOL-1-O-[ALPHA-L-RHAMNOPYRANOSYL(1-2)-ALPHA-L-ARABINOPYRANOSIDE]-26-O-BETA-D-GLUCOPYRANOSIDE	INACTIVE
57	ANTIPROLIFERATION ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VITRO	FUROSTA-5-20(22)-25(27)-TRIEN-1-BETA-3-BETA-26-TRIOL-1-O-[ALPHA-L-RHAMNOPYRANOSYL(1-2)-ALPHA-L-ARABINOPYRANOSIDE]-26-O-BETA-D-GLUCOPYRANOSIDE	INACTIVE
58	Not specified	ISOLATION AND IDENTIFICATION OFQUANTITATIVE DATA	SPIROSTA-5-25(27)-DIEN-1-BETA-3-BETA-DIOL-1-O-ALPHA-L-ARABINOPYRANOSIDE	None
59	ANTIPROLIFERATION ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VITRO	SPIROSTA-5-25(27)-DIEN-1-BETA-3-BETA-DIOL-1-O-ALPHA-L-ARABINOPYRANOSIDE	ACTIVE
60	ANTIPROLIFERATION ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VITRO	SPIROSTA-5-25(27)-DIEN-1-BETA-3-BETA-DIOL-1-O-ALPHA-L-ARABINOPYRANOSIDE	ACTIVE
61	ANTIPROLIFERATION ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VITRO	SPIROSTA-5-25(27)-DIEN-1-BETA-3-BETA-DIOL-1-O-ALPHA-L-ARABINOPYRANOSIDE	ACTIVE
62	Not specified	ISOLATION AND IDENTIFICATION OFQUANTITATIVE DATA	SPIROSTA-5-25(27)-DIEN-1-BETA-3-BETA-DIOL-1-O-[ALPHA-L-RHAMNOPYRANOSYL(1-2)]-ALPHA-L-ARABINOPYRANOSIDE	None
63	ANTIPROLIFERATION ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VITRO	SPIROSTA-5-25(27)-DIEN-1-BETA-3-BETA-DIOL-1-O-[ALPHA-L-RHAMNOPYRANOSYL(1-2)]-ALPHA-L-ARABINOPYRANOSIDE	ACTIVE
64	ANTIPROLIFERATION ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VITRO	SPIROSTA-5-25(27)-DIEN-1-BETA-3-BETA-DIOL-1-O-[ALPHA-L-RHAMNOPYRANOSYL(1-2)]-ALPHA-L-ARABINOPYRANOSIDE	ACTIVE
65	ANTIPROLIFERATION ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VITRO	SPIROSTA-5-25(27)-DIEN-1-BETA-3-BETA-DIOL-1-O-[ALPHA-L-RHAMNOPYRANOSYL(1-2)]-ALPHA-L-ARABINOPYRANOSIDE	ACTIVE
66	Not specified	ISOLATION AND IDENTIFICATION OFQUANTITATIVE DATA	PREGNA-5-16-DIEN-1-BETA-3-BETA-DIOL-1-O-[ALPHA-L-RHAMNOPYRANOSYL(1-2)]-ALPHA-L-ARABINOPYRANOSIDE	None
67	ANTIPROLIFERATION ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VITRO	PREGNA-5-16-DIEN-1-BETA-3-BETA-DIOL-1-O-[ALPHA-L-RHAMNOPYRANOSYL(1-2)]-ALPHA-L-ARABINOPYRANOSIDE	INACTIVE
68	ANTIPROLIFERATION ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VITRO	PREGNA-5-16-DIEN-1-BETA-3-BETA-DIOL-1-O-[ALPHA-L-RHAMNOPYRANOSYL(1-2)]-ALPHA-L-ARABINOPYRANOSIDE	INACTIVE
69	ANTIPROLIFERATION ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VITRO	PREGNA-5-16-DIEN-1-BETA-3-BETA-DIOL-1-O-[ALPHA-L-RHAMNOPYRANOSYL(1-2)]-ALPHA-L-ARABINOPYRANOSIDE	INACTIVE

Citation 88005

Citation Details

Summary

Organisms and Their Experiments (1)

Dracaena angustifolia (AGAVACEAE)

Show SPARQL Queries (1)

Query 1